Is Tecentriq + Carboplatin + Pemetrexed Effective for Lung Cancer?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On August 21, 2023, Ernest Nadal and colleagues from L’Hospitalet de Llobregat published the results of a Phase 2 clinical trial in the "Journal of Clinical Oncology." The study evaluated the efficacy and safety of Tecentriq (atezolizumab) + Carboplatin + Pemetrexed in treatment-naive patients with advanced non-squamous non-small cell lung cancer (NSCLC) and brain metastases.
In this Phase 2 trial, 42 treatment-naive patients with advanced non-squamous NSCLC and brain metastases received Tecentriq + Carboplatin + Pemetrexed (for 4-6 cycles, followed by maintenance Tecentriq + Pemetrexed for up to 2 years or until disease progression). The primary endpoints were the 12-week progression-free survival (PFS) rate and the incidence of Grade 3 or higher adverse events from the start of treatment through week 9.
The 12-week PFS rate was 62.2%, and the incidence of Grade 3 or higher adverse events through week 9 was 27.5%. Most neurological adverse events were Grade 1-2, with Grade 3-4 events occurring in 12.5% (N=5) of patients.
Other endpoints included a median intracranial PFS of 6.9 months, an intracranial response rate of 42.7%, a median overall survival (OS) of 11.8 months, and a 2-year OS rate of 27.5%.
Based on these Phase 2 results, Ernest Nadal stated that Tecentriq + Carboplatin + Pemetrexed demonstrated favorable anti-tumor activity and a manageable safety profile in treatment-naive patients with advanced non-squamous NSCLC and brain metastases.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4